New developments in antibody therapy for acute myeloid leukemia
- 1 August 2003
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 30 (4) , 502-508
- https://doi.org/10.1016/s0093-7754(03)00234-3
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotypeLeukemia, 2002
- Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid LeukemiaBioconjugate Chemistry, 2001
- Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First RelapseJournal of Clinical Oncology, 2001
- Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cellsBlood, 2001
- Acute Myeloid LeukemiaHematology-American Society Hematology Education Program, 2001
- Targeting Leukemia Cells with Gemtuzumab OzogamicinCancer Practice, 2000
- Management of Acute Myeloid Leukemia in Elderly PatientsJournal of Clinical Oncology, 1999
- Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)Blood, 1999
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999
- Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin ImmunoconjugateBlood, 1999